英国Shire开发的碳酸镧能够延长肾病患者生命

 
根据2005年11月发表在《肾脏疾病临床实践》的研究报道，碳酸镧(Fosrenal)对终末期肾脏疾病(ESRD)患者而言，是一种安全的、耐受性很好的药物，能够在70％患者中降低并维持平均血清磷酸盐水平达3年之久。

对全球将近1百万面临高磷酸血症严重并发症危险的患者而言，这些研究结果是令人振奋的消息，高磷酸血症是血液中出现过量磷酸盐所导致的疾病。这种疾病是许多ESRD患者几乎不可避免的结果，在许多患者没有得到有效治疗。接受血液透析的患者低磷酸盐饮食是十分必要的，但是对许多严格控制饮食，血中磷酸盐水平仍然升高。

如果不能有效治疗，高磷酸盐血症会导致肾性骨营养不良，或者导致心血管疾病，这几乎导致半数接受透析治疗患者的死亡。Fosrenal通过结合消化道食物中的磷酸盐来发挥作用。一旦结合Fosrenal复合物不能通过肠道而进入血液，从而被机体排除体外，显著地降低磷酸盐的吸收。Fosrenal是由英国Shire全球临床医学(Basingstoke, UK)公司研制开发的。

Drug Aids Renal Patients Long Term
 
Lanthanum carbonate (Fosrenal) has been found to be safe and tolerable in patients with end-stage renal disease (ESRD) while successfully reducing and maintaining mean serum phosphate levels in 70% of patients for up to three years, according to a study in the November 2005 issue of Nephron Clinical Practice.

These results are promising news for the nearly one million people worldwide at risk for the serious consequences of hyperphosphatemia, a condition caused by an excess amount of phosphate in the blood. The condition is an almost inevitable consequence of ESRD and remains poorly controlled in many patients. A low phosphate diet is essential for managing dialysis patients but many have highly elevated levels despite maintaining a strict diet.

If not well-managed, hyperphosphatemia can cause renal osteodystrophy or contribute to cardiovascular disease, which accounts for almost half of all deaths among dialysis patients. Fosrenal works by binding to dietary phosphate in the gastrointestinal tract. Once bound, the Fosrenal complex cannot pass through the intestinal lining into the bloodstream and is eliminated from the body, decreasing phosphate absorption significantly. Fosrenal was developed by Shire Global Clinical Medicine (Basingstoke, UK).